{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:05:14Z","timestamp":1758405914440,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Women with BRCA1 and BRCA2 (BRCA1\/2) pathogenic\/likely pathogenic (P\/LP) variants have a higher risk to develop breast and ovarian cancer. In structured high-risk clinics, risk-reducing measures are adopted. This study aimed at characterizing these women and identify factors that may have influenced their choice between risk reduction mastectomy (RRM) and intensive breast surveillance (IBS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study reviewed retrospectively 187 clinical records of affected and unaffected women with P\/LP variants of the BRCA1\/2 genes, from 2007 to 2022, of which 50 chose RRM, while 137 chose IBS. The research focused on personal and family history and tumor characteristics and their relation with the preventive option chosen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among women with personal history of breast cancer, a higher proportion opted for RRM compared to those asymptomatic (34.2% vs 21.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.049), with younger age determining the option for RRM (38.5\u00a0years vs 44.0\u00a0years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Among women with personal history of ovarian cancer, a higher proportion opted for RRM compared to those without that history (62.5% vs 25.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.033), with younger age determining the option for RRM (42.6\u00a0years vs 62.7\u00a0years, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). Women who had bilateral salpingo-oophorectomy were more likely to choose RRM than those who did not (37.3% vs 18.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Family history was not associated with preventive option (33.3% vs 25.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.346).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The decision for the preventive option is multifactorial. In our study, personal history of breast or ovarian cancer, younger age at diagnosis, and previous bilateral salpingo-oophorectomy were associated with the choice of RRM. Family history was not associated with the preventive option.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04663-9","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T14:02:51Z","timestamp":1679925771000},"page":"7529-7538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differences among a Portuguese cohort of BRCA pathogenic\/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-1945","authenticated-orcid":false,"given":"Sandra","family":"Torres","sequence":"first","affiliation":[]},{"given":"B\u00e1rbara","family":"Peleteiro","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9","family":"Magalh\u00e3es","sequence":"additional","affiliation":[]},{"given":"Luzia","family":"Garrido","sequence":"additional","affiliation":[]},{"given":"Susy","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Lu\u00eds","family":"Fougo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"19","key":"4663_CR1","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1002\/cncr.34393","volume":"128","author":"CA Bargon","year":"2022","unstructured":"Bargon CA, Young-Afat DA, Ikinci M, Braakenburg A, Rakhorst HA, Mureau MAM et al (2022) Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction\u2014a systematic review and meta-analysis. Cancer 128(19):3449\u20133469. https:\/\/doi.org\/10.1002\/cncr.34393","journal-title":"Cancer"},{"key":"4663_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2017.08.017","volume":"86","author":"L Biganzoli","year":"2017","unstructured":"Biganzoli L, Marotti L, Hart CD, Cataliotti L, Cutuli B, Kuhn T et al (2017) Quality indicators in breast cancer care: an update from the EUSOMA working group. Eur J Cancer 86:59\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.017","journal-title":"Eur J Cancer"},{"key":"4663_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.breast.2020.02.003","volume":"51","author":"L Biganzoli","year":"2020","unstructured":"Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE et al (2020) The requirements of a specialist breast centre. Breast 51:65\u201384. https:\/\/doi.org\/10.1016\/j.breast.2020.02.003","journal-title":"Breast"},{"issue":"1","key":"4663_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM et al (2021) Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19(1):77\u2013102. https:\/\/doi.org\/10.6004\/jnccn.2021.0001","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"4663_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ejca.2011.10.020","volume":"48","author":"M den Heijer","year":"2012","unstructured":"den Heijer M, Seynaeve C, Timman R, Duivenvoorden HJ, Vanheusden K, Tilanus-Linthorst M et al (2012) Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur J Cancer 48(9):1263\u20131268. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.020","journal-title":"Eur J Cancer"},{"issue":"30","key":"4663_CR6","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):7491\u20137496. https:\/\/doi.org\/10.1200\/JCO.2004.00.7138","journal-title":"J Clin Oncol"},{"issue":"10","key":"4663_CR7","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-017-5976-2","volume":"24","author":"E Gilbert","year":"2017","unstructured":"Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M (2017) Differences among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Ann Surg Oncol 24(10):3048\u20133054. https:\/\/doi.org\/10.1245\/s10434-017-5976-2","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4663_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.breast.2011.01.006","volume":"20","author":"I Haroun","year":"2011","unstructured":"Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E et al (2011) Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast 20(3):254\u2013258. https:\/\/doi.org\/10.1016\/j.breast.2011.01.006","journal-title":"Breast"},{"issue":"3","key":"4663_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","volume":"177","author":"BAM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collee M, Meijers-Heijboer HEJ et al (2019) Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 177(3):723\u2013733. https:\/\/doi.org\/10.1007\/s10549-019-05345-2","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4663_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","volume":"174","author":"DA Henry","year":"2019","unstructured":"Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC et al (2019) Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat 174(1):39\u201345. https:\/\/doi.org\/10.1007\/s10549-018-5057-7","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4663_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","volume":"142","author":"SL Ingham","year":"2013","unstructured":"Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F et al (2013) Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat 142(3):611\u2013618. https:\/\/doi.org\/10.1007\/s10549-013-2765-x","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"4663_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4048\/jbc.2020.23.e61","volume":"23","author":"SM Jung","year":"2020","unstructured":"Jung SM, Ryu JM, Park HS, Park JS, Kang E, Lee S et al (2020) Trends in risk-reducing mastectomy and risk-reducing salpingo-oophorectomy in Korean carriers of the BRCA1\/2 Mutation. J Breast Cancer 23(6):647\u2013655. https:\/\/doi.org\/10.4048\/jbc.2020.23.e61","journal-title":"J Breast Cancer"},{"issue":"Suppl 2","key":"4663_CR13","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.breast.2015.07.022","volume":"24","author":"TA King","year":"2015","unstructured":"King TA, Pilewskie M, Morrow M (2015) Optimal surgical management for high-risk populations. Breast 24(Suppl 2):S91\u2013S95. https:\/\/doi.org\/10.1016\/j.breast.2015.07.022","journal-title":"Breast"},{"issue":"23","key":"4663_CR14","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112","journal-title":"JAMA"},{"issue":"4","key":"4663_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","volume":"212","author":"KK Ludwig","year":"2016","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212(4):660\u2013669. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.010","journal-title":"Am J Surg"},{"issue":"5","key":"4663_CR16","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","volume":"234","author":"M Mahdavi","year":"2019","unstructured":"Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R et al (2019) Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol 234(5):5741\u20135750. https:\/\/doi.org\/10.1002\/jcp.27464","journal-title":"J Cell Physiol"},{"issue":"9","key":"4663_CR17","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/pon.5166","volume":"28","author":"S Manoukian","year":"2019","unstructured":"Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C (2019) Risk-reducing surgery in BRCA1\/BRCA2 mutation carriers: are there factors associated with the choice? Psychooncology 28(9):1871\u20131878. https:\/\/doi.org\/10.1002\/pon.5166","journal-title":"Psychooncology"},{"issue":"11","key":"4663_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822. https:\/\/doi.org\/10.1093\/jnci\/djt095","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"4663_CR19","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/bjc.2011.120","volume":"104","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384\u20131392. https:\/\/doi.org\/10.1038\/bjc.2011.120","journal-title":"Br J Cancer"},{"issue":"1","key":"4663_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15\u201321. https:\/\/doi.org\/10.1038\/s41416-019-0446-1","journal-title":"Br J Cancer"},{"issue":"9","key":"4663_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4(9):665\u2013676. https:\/\/doi.org\/10.1038\/nrc1431","journal-title":"Nat Rev Cancer"},{"key":"4663_CR22","unstructured":"NCCN guidelines for detection, prevention, & risk reduction. https:\/\/www.nccn.org\/professionals\/physician_gls\/#detection. Accessed 20 Nov 2022"},{"key":"4663_CR23","unstructured":"Petrucelli N, Daly MB, Pal T (1993) BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH et al (eds) GeneReviews((R)) Seattle (WA). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20301425. Accessed 24 Nov 2022"},{"issue":"2","key":"4663_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","volume":"57","author":"D Saslow","year":"2007","unstructured":"Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75\u201389. https:\/\/doi.org\/10.3322\/canjclin.57.2.75","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"4663_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/000313480507101209","volume":"71","author":"AJ Stolier","year":"2005","unstructured":"Stolier AJ, Corsetti RL (2005) Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1\/2 mutation. Am Surg 71(12):1031\u20131033","journal-title":"Am Surg"},{"issue":"4","key":"4663_CR26","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clbc.2021.01.008","volume":"21","author":"G Wei","year":"2021","unstructured":"Wei G, Kumar A, Lee MC, Wang X (2021) Influential factors on risk-reduction mastectomy in a high-risk breast cancer population with genetic predispositions. Clin Breast Cancer 21(4):e427\u2013e433. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.008","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04663-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:40:33Z","timestamp":1690479633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4663"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04663-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"29 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o (124\/2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The retrospective nature of the analysis supported the informed consent waiver, for the sake of feasibility. This research ensured the privacy of patient data, since any sort of personal information that allows identification was not used or shown in the database built.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}